Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

ProShares UltraPro Short QQQ, Hims & Hers Health, and Teleflex are the three Mid Cap stocks to watch today, according to MarketBeat’s stock screener tool. Mid cap stocks are shares of companies with ...

Learn more about whether Hims & Hers Health, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Alignment Healthcare, Inc. or Hims & Hers Health, Inc. is a better investment based on AAII's A+ ...